US Stock MarketDetailed Quotes
NVCT Nuvectis Pharma
- 6.310
- -0.100-1.56%
Close Nov 4 16:00 ET
- 6.400
- +0.090+1.43%
Post 20:02 ET
117.70MMarket Cap-4891P/E (TTM)
6.750High6.305Low86.02KVolume6.700Open6.410Pre Close556.92KTurnover1.30%Turnover RatioLossP/E (Static)18.65MShares12.10052wk High9.39P/B41.93MFloat Cap5.85052wk Low--Dividend TTM6.64MShs Float20.920Historical High--Div YieldTTM6.94%Amplitude3.080Historical Low6.474Avg Price1Lot Size
About Nuvectis Pharma Company
Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.
Company Profile
SymbolNVCT
Company NameNuvectis Pharma
Listing DateFeb 4, 2022
Issue Price5.00
Founded2020
CEOMr. Ron Bentsur
MarketNASDAQ
Employees13
Fiscal Year Ends12-31
Address1 Bridge Plaza,Suite 275,2nd floor
CityFort Lee
ProvinceNew Jersey
CountryUnited States of America
Zip Code07024
Phone1-201-614-3151
Websitehttp://nuvectis.com
Company Executives
- Name
- Position
- Salary
- Ron Bentsur
- Chairman of the Board, Chief Executive Officer and President
- 2.69M
- Enrique Poradosu
- Executive Vice President, Chief Scientific and Business Officer
- 1.56M
- Shay Shemesh
- Executive Vice President, Chief Development and Operations Officer
- 1.56M
- Michael J. Carson
- Vice President of Finance, Principal Financial and Accounting Officer
- --
- Matthew L. Kaplan
- Independent Director
- 375.80K
- Kenneth Hoberman
- Independent Director
- 385.80K
- James F. Oliviero, III
- Independent Director
- 385.80K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data